Argus Investors Counsel Inc. Has $417,000 Stake in Stryker Corporation $SYK

Argus Investors Counsel Inc. trimmed its stake in Stryker Corporation (NYSE:SYK) by 54.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,269 shares of the medical technology company’s stock after selling 1,535 shares during the period. Argus Investors Counsel Inc.’s holdings in Stryker were worth $417,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at $26,000. Sankala Group LLC bought a new position in shares of Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker during the 4th quarter worth about $27,000. Finally, DJE Kapital AG bought a new stake in Stryker during the 4th quarter worth about $28,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by insiders.

Stryker Stock Down 0.0%

Shares of NYSE SYK opened at $326.41 on Monday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a market cap of $125.13 billion, a P/E ratio of 37.78, a P/E/G ratio of 2.09 and a beta of 0.77. The firm has a 50 day moving average price of $309.80 and a 200 day moving average price of $338.75.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. JPMorgan Chase & Co. lowered their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on Stryker in a report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.